Literature DB >> 8348382

Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging.

C Bordat1, A Constans, O Bouet, I Blanc, C L Trubert, R Girot, G Cournot.   

Abstract

Iron overload occurs frequently in thalassemia as a consequence of regular blood transfusions, and iron has been found to accumulate in bone, but skeletal toxicity of iron is not clearly established. In this study, bone biopsies of thalassemic patients were investigated by light (n = 6) and electron microscopy (n = 8) in order to analyze iron distribution and possible iron-associated cellular lesions. Sections (5 microns thick) were used for histomorphometry and iron histochemistry. Ultrathin sections were examined with an energy filtering transmission electron microscope. Iron was identified by electron energy loss spectroscopy (EELS), and iron distribution was visualized by electron spectroscopic imaging (ESI) associated with computer-assisted treatment (two-window method). This study shows that EELS allows the detection of 4500-9000 iron atoms, and that computer-assisted image processing is essential to eliminate background and to obtain the net distribution of an element by ESI. This study shows also that stainable iron was present along trabecular surfaces, mineralizing surfaces, and on cement lines in the biopsies of all patients. Moreover, iron was detected by EELS in small granules (diffusely distributed or condensed in large clusters), in osteoid tissue, and in the cytoplasm of bone cells, but not in the mineralized matrix. The shape and size (9-13 nm) of these granules were similar to those reported for ferritin. As for iron toxicity, all patients had osteoid volume and thickness and osteoblast surface in the normal range. Stainable iron surfaces did not correlate with osteoblast surfaces, plasma ferritin concentrations, or the duration of transfusion therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348382     DOI: 10.1007/BF01352012

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  24 in total

1.  Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease.

Authors:  T Diamond; R Pojer; D Stiel; A Alfrey; S Posen
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

2.  Iron overload and bone disease in chronic dialysis patients.

Authors:  F L Van de Vyver; W J Visser; P C D'Haese; M E De Broe
Journal:  Contrib Nephrol       Date:  1988       Impact factor: 1.580

3.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

4.  Elemental mapping by energy filtration: advantages, limitations, and compromises.

Authors:  F P Ottensmeyer
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

5.  Electron density map of apoferritin at 2.8-A resolution.

Authors:  S H Banyard; D K Stammers; P M Harrison
Journal:  Nature       Date:  1978-01-19       Impact factor: 49.962

6.  Spatial resolution and detection sensitivity in microanalysis by electron loss selected imaging.

Authors:  K M Adamson-Sharpe; F P Ottensmeyer
Journal:  J Microsc       Date:  1981-06       Impact factor: 1.758

7.  Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure.

Authors:  G Witmer; A Margolis; O Fontaine; J Fritsch; G Lenoir; M Broyer; S Balsan
Journal:  Kidney Int       Date:  1976-11       Impact factor: 10.612

8.  Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia.

Authors:  M C de Vernejoul; R Girot; J Gueris; L Cancela; S Bang; J Bielakoff; C Mautalen; D Goldberg; L Miravet
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

9.  Bone disease in children with homozygous beta-thalassemia.

Authors:  L Rioja; R Girot; M Garabédian; G Cournot-Witmer
Journal:  Bone Miner       Date:  1990-01
View more
  6 in total

Review 1.  Secondary Osteoporosis and Metabolic Bone Diseases.

Authors:  Mahmoud M Sobh; Mohamed Abdalbary; Sherouk Elnagar; Eman Nagy; Nehal Elshabrawy; Mostafa Abdelsalam; Kamyar Asadipooya; Amr El-Husseini
Journal:  J Clin Med       Date:  2022-04-24       Impact factor: 4.964

2.  Iron sources used by the nonpathogenic lactic acid bacterium Lactobacillus sakei as revealed by electron energy loss spectroscopy and secondary-ion mass spectrometry.

Authors:  Philippe Duhutrel; Christian Bordat; Ting-Di Wu; Monique Zagorec; Jean-Luc Guerquin-Kern; Marie-Christine Champomier-Vergès
Journal:  Appl Environ Microbiol       Date:  2009-11-20       Impact factor: 4.792

Review 3.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

4.  Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging.

Authors:  C Bordat; A Constans; O Bouet; I Blanc; C L Trubert; R Girot; G Cournot
Journal:  Calcif Tissue Int       Date:  1993-07       Impact factor: 4.333

Review 5.  Clinical Impact and Cellular Mechanisms of Iron Overload-Associated Bone Loss.

Authors:  Viktória Jeney
Journal:  Front Pharmacol       Date:  2017-02-21       Impact factor: 5.810

Review 6.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.